Ipsen Confident in U.S. Neurology Push Despite Dysport Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
Neither FDA’s REMS request nor the prospect of competing with Allergan’s Botox appears to be spoiling Ipsen’s plans to stake a U.S. neurology stronghold.
You may also be interested in...
Deals Of The Week: Forma/Boehringer Ingelheim, Biogen/Isis, Alnylam/Arrowhead
Industry business-development executives rang in the New Year with a half-dozen deals, including Forma’s second big partnership in six months and a joint licensing agreement between Alnylam and Arrowhead.
Ipsen's First Focus Is Endocrinology As Firm Moves Toward Specialty Care
As Ipsen shifts away from an emphasis on primary care and toward specialty care therapies – a move straight out of Big Pharma’s playbook – endocrinology will become a pillar of its specialty care pipeline.
Ipsen's First Focus Is Endocrinology As Firm Moves Toward Specialty Care
As Ipsen shifts away from an emphasis on primary care and toward specialty care therapies – a move straight out of Big Pharma’s playbook – endocrinology will become a pillar of its specialty care pipeline.